IART
NEUTRAL
$9.9
Live
Integra LifeSciences Holdings Corporation · NASDAQ
Target $15.57
(+57.3%)
$8.7
52W Range
$17.54
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 12, 2026
Market cap
$771.58M
P/E
N/A
ROE
-39.9%
Profit margin
-31.6%
Debt/Equity
1.95
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
IART presents as a classic deep-value turnaround candidate with a stable Piotroski F-Score of 6/9, indicating reasonable operational health despite severe price depreciation. The company is trading at a significant discount to book value (P/B 0.74) and possesses a very low forward P/E of 3.86, suggesting the market has over-priced the risk. However, negative net profit margins (-31.58%) and stagnant revenue growth (-1.70%) offset the valuation appeal. The stark contrast between the current price ($9.90) and the analyst target ($15.57) indicates potential upside, but the bearish technical trend remains a primary headwind.
Key Strengths
Deep value valuation with P/B of 0.74 and P/S of 0.47
Strong short-term liquidity with a Current Ratio of 2.54
Stable financial health baseline (Piotroski F-Score 6/9)
Healthy Gross Margins (56.22%) indicating strong core product pricing
Significant analyst price target upside (~57% to $15.57)
Key Risks
Severe long-term price erosion (-85.7% over 5 years)
Negative net profit margins (-31.58%) impacting bottom-line stability
Stagnant to declining revenue growth (YoY -1.70%)
Elevated Debt/Equity ratio of 1.95
Bearish technical trend (0/100 score)
AI Fair Value Estimate
Based on comprehensive analysis
$13.2
+33.3% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
41
Moderate
90
35
15
65
0
AI Verdict
Speculative Value Play
Key drivers: Extreme valuation discount, Negative earnings growth, Strong liquidity vs high leverage, Catastrophic historical price performance
Confidence
80%
Value
90/100
Ref P/E, PEG, P/B
Positives
- Forward P/E of 3.86 is exceptionally low
- PEG ratio of 0.67 suggests undervaluation relative to growth
- Trading below book value (P/B 0.74)
Watchpoints
- Lack of current positive earnings to support P/E
Future
35/100
Ref Growth rates
Positives
- Recent Q/Q EPS growth spike
Watchpoints
- Negative YoY revenue growth
- Negative Q/Q revenue growth
Past
15/100
Ref Historical trends
Positives
- Consistent earnings beats in 2020-2022
Watchpoints
- 5-year price change of -85.7%
- 1-year price change of -43.2%
Health
65/100
Ref Piotroski F-Score, Debt/Equity
Positives
- Piotroski F-Score 6/9 (Stable)
- Current Ratio 2.54 is robust
Watchpoints
- Debt/Equity 1.95 is high for the sector
- Negative ROE (-39.90%)
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend payments
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$9.9
Analyst Target
$15.57
Upside/Downside
+57.3%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for IART and closest competitors.
Updated 2026-04-10
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
IART
Integra LifeSciences Holdings Corporation
Primary
|
-85.7% | -83.0% | -43.2% | -25.8% | +3.0% | +3.9% |
|
ARVN
Arvinas, Inc.
Peer
|
-84.3% | -57.8% | +42.5% | +57.4% | -7.0% | -10.4% |
|
AMN
AMN Healthcare Services, Inc.
Peer
|
-72.8% | -78.8% | -26.3% | +3.5% | +28.0% | +7.7% |
|
BGM
BGM Group Ltd.
Peer
|
-90.8% | -38.2% | -66.0% | -64.4% | -12.5% | 0.0% |
|
GDRX
GoodRx Holdings, Inc.
Peer
|
-94.7% | -62.4% | -53.9% | -53.5% | -10.0% | +5.4% |
IAR
Integra LifeSciences Holdings Corporation
Primary
5Y
-85.7%
3Y
-83.0%
1Y
-43.2%
6M
-25.8%
1M
+3.0%
1W
+3.9%
ARV
Arvinas, Inc.
Peer
5Y
-84.3%
3Y
-57.8%
1Y
+42.5%
6M
+57.4%
1M
-7.0%
1W
-10.4%
AMN
AMN Healthcare Services, Inc.
Peer
5Y
-72.8%
3Y
-78.8%
1Y
-26.3%
6M
+3.5%
1M
+28.0%
1W
+7.7%
BGM
BGM Group Ltd.
Peer
5Y
-90.8%
3Y
-38.2%
1Y
-66.0%
6M
-64.4%
1M
-12.5%
1W
0.0%
GDR
GoodRx Holdings, Inc.
Peer
5Y
-94.7%
3Y
-62.4%
1Y
-53.9%
6M
-53.5%
1M
-10.0%
1W
+5.4%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
3.86
PEG Ratio
0.67
P/B Ratio
0.74
P/S Ratio
0.47
EV/Revenue
1.55
EV/EBITDA
8.54
Market Cap
$771.58M
Profitability
Profit margins and return metrics
Profit Margin
-31.58%
Operating Margin
12.44%
Gross Margin
56.23%
ROE
-39.9%
ROA
2.39%
Growth
Revenue and earnings growth rates
Revenue Growth
-1.7%
Earnings Growth
N/A
Q/Q Revenue Growth
-1.74%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
1.95
High debt
Current Ratio
2.54
Strong
Quick Ratio
1.19
Good
Cash/Share
$3.38
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.4B
Gross Margin
50.8%
Op. Margin
5.3%
Net Margin
-0.4%
Total Assets
$3.6B
Liabilities
$2.6B
Equity
$1.0B
Debt/Equity
2.45x
Operating CF
$0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
-166%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-04
$N/A
2026-02-26
$0.83
+3.7% surprise
2025-10-30
$-0.07
-203.7% surprise
2025-07-31
$0.45
+4.4% surprise
Healthcare Sector Comparison
Comparing IART against 264 companies in the Healthcare sector
(20 bullish, 87 neutral, 157 bearish)
Return on Equity (ROE)
-39.9%
This Stock
vs
-46.09%
Sector Avg
-13.4%
(Below Avg)
Profit Margin
-31.58%
This Stock
vs
-19.58%
Sector Avg
+61.3%
(Superior)
Debt to Equity
1.95
This Stock
vs
4.1
Sector Avg
-52.4%
(Less Debt)
Revenue Growth
-1.7%
This Stock
vs
88.16%
Sector Avg
-101.9%
(Slower)
Current Ratio
2.54
This Stock
vs
3.58
Sector Avg
-28.9%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
IART
Integra LifeSciences...
|
NEUTRAL | $771.58M | - | -39.9% | -31.6% | $9.9 | |
|
ARVN
Arvinas, Inc.
|
BEARISH | $782.25M | - | -16.2% | -30.8% | $12.18 | Compare |
|
AMN
AMN Healthcare Services, Inc.
|
BEARISH | $787.1M | - | -35.9% | -10.1% | $20.49 | Compare |
|
BGM
BGM Group Ltd.
|
BEARISH | $746.32M | - | -16.5% | -26.3% | $3.72 | Compare |
|
GDRX
GoodRx Holdings, Inc.
|
BEARISH | $739.96M | 24.0 | 4.5% | 3.8% | $2.16 | Compare |
IART
Integra...
NEUTRAL
Mkt Cap
$772M
P/E
-
ROE
-39.9%
Price
$9.9
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-11 | SINGH HARVINDER | Officer | Stock Award | 20,138 | - |
| 2026-01-06 | POUL MOJDEH | Chief Executive Officer | Stock Award | 1,390 | - |
| 2025-11-05 | GRAVES JEFFREY A. | Director | Purchase | 9,000 | $102,150 |
SINGH HARVINDER
Officer
2026-03-11
20,138 shares
POUL MOJDEH
Chief Executive Officer
2026-01-06
1,390 shares
GRAVES JEFFREY A.
Director
2025-11-05
9,000 shares
·
$102,150
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
NONE
7 analysts
Citigroup
2026-03-11
Sell
Sell
Wells Fargo
2026-02-27
Equal-Weight
Equal-Weight
Truist Securities
2025-11-03
Hold
Hold
Citigroup
2025-10-31
Sell
Sell
JP Morgan
2025-10-31
Underweight
Underweight
Truist Securities
2025-10-15
Hold
Hold
Past News Coverage
Recent headlines mentioning IART from our newsroom.
Newest → oldest
No matching news yet.